Jun Wu
Impact in
- Biomaterials top 0.1%
- Nanoparticle-Based Drug Delivery
- Electrospun Nanofibers in Biomedical Applications
- Cancer Research top 0.5%
- MicroRNA in disease regulation
Papers in
-
- RNA modifications and cancer 9
- Oncology 45
- Cytokine Signaling Pathways and Interactions 12
- Cancer-related Molecular Pathways 9
- Co-authors
- Hiroshi Maeda (4 shared papers)Tomohiro Sawa (3 shared papers)K. Hori (1 shared paper)Yasuhiro Matsumura (1 shared paper)Takaaki Akaike (7 shared papers)Ren‐Ke Li (28 shared papers)Richard D. Weisel (19 shared papers)Kwok‐Pui Fung (7 shared papers)
- Journals
- PLoS ONE (8 papers)Cancer Research (7 papers)Cancer Biology & Therapy (4 papers)Biochemical Pharmacology (4 papers)Biochemistry and Cell Biology (4 papers)
- Partner nations
- ChinaUnited StatesCanada
In The Last Decade
Jun Wu
237 papers receiving 14.7k citations
Jun Wu's Hit Papers
Peers
Comparison fields: 5 of 165
- Biomaterials 4.2k
- Cancer Research 1.6k
- Molecular Biology 6.3k
- Biomedical Engineering 3.7k
- Oncology 1.9k
Countries citing papers authored by Jun Wu
This map shows the geographic impact of Jun Wu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jun Wu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jun Wu more than expected).
Fields of papers citing papers by Jun Wu
This network shows the impact of papers produced by Jun Wu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jun Wu. The network helps show where Jun Wu may publish in the future.
Co-authors
The 25 scholars most cited alongside Jun Wu, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 247 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review Hit paper breakdown → | 2000 | 5305 |
| 2 | The Enhanced Permeability and Retention (EPR) Effect: The Significance of the Concept and Methods to Enhance Its Application Hit paper breakdown → | 2021 | 675 |
| 3 | 1998 | 371 | |
| 4 | 2012 | 331 | |
| 5 | 2017 | 328 | |
| 6 | 2016 | 321 | |
| 7 | 2011 | 256 | |
| 8 | 2011 | 243 | |
| 9 | 1997 | 186 | |
| 10 | 1996 | 180 | |
| 11 | 2009 | 174 | |
| 12 | 2004 | 174 | |
| 13 | Modulation of enhanced vascular permeability in tumors by a bradykinin antagonist, a cyclooxygenase inhibitor, and a nitric oxide scavenger. | 1998 | 169 |
| 14 | 2004 | 162 | |
| 15 | 2001 | 116 | |
| 16 | 2002 | 115 | |
| 17 | 2018 | 109 | |
| 18 | 2012 | 109 | |
| 19 | 1991 | 107 | |
| 20 | 2010 | 101 |
About Jun Wu
Jun Wu is a scholar working on Molecular Biology, Oncology, Cancer Research, Immunology and Surgery, having authored 247 papers that have together received 15.0k indexed citations. Recurring topics across this work include Cytokine Signaling Pathways and Interactions (12 papers), Cancer Mechanisms and Therapy (12 papers), Cancer-related Molecular Pathways (9 papers), Tissue Engineering and Regenerative Medicine (9 papers), MicroRNA in disease regulation (9 papers), RNA modifications and cancer (9 papers), Monoclonal and Polyclonal Antibodies Research (8 papers) and Autophagy in Disease and Therapy (8 papers). The work is most often cited by research in Biomaterials (4.2k citations), Cancer Research (1.6k citations), Molecular Biology (6.3k citations), Biomedical Engineering (3.7k citations) and Oncology (1.9k citations). Jun Wu has collaborated with scholars based in China, United States and Canada. Frequent co-authors include Hiroshi Maeda, Tomohiro Sawa, K. Hori, Yasuhiro Matsumura, Takaaki Akaike, Ren‐Ke Li, Richard D. Weisel, Kwok‐Pui Fung, Tai-Wing Wu and Xiwei Wu. Their work appears in journals such as PLoS ONE, Cancer Research, Cancer Biology & Therapy, Biochemical Pharmacology and Biochemistry and Cell Biology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.